Patents by Inventor Shweta Singh

Shweta Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240354350
    Abstract: Example systems and methods provide input suggestions to a user to improve user experience on user devices. The input suggestions can be fill information from another app on device to the present app being used by user, information for performing a search (without the user having to copy-paste data or entering the data manually), responses to a message/notification received by the user, information/content/data to be shared between apps (without switching between apps), and emojis/GIFs that can be used by the user. The method includes analyzing one or more content of one or more screen displayed on device, generating at least one of a logical tree structure and a data mashup model of the one or more analyzed content for each screen, and providing a recommendation to a user. The recommendation can be a connected action or an input suggestion.
    Type: Application
    Filed: July 1, 2024
    Publication date: October 24, 2024
    Inventors: Naresh PURRE, Sriram Shashank, Sri Lakshmi Punuru, Barath Raj Kandur Raja, Vanraj Vala, Aayush Yadav, Aditi Anil Kagane, Sudeep Kumar Kodali, Rishabh Kumar, Srinivasa Rao Siddi, Manjunath Bhimappa Ujjinakoppa, Mansoor Variyathapara Mohammed, Hemant Tiwari, Dwakara Bhamidipati Sreevatsa, Ankita Bhardwaj, Vipin Rao, Likhith Amarvaj, Vibhav Agarwal, Yashwant Singh Saini, Himanshu Arora, Muthu Kumaran, Seungseok Kang, Sanguk Jeon, Jaehoon Park, Pilsik Choi, Hojun Jaygarl, Shweta Ratanpura, Mritunjai Chandra
  • Publication number: 20240210479
    Abstract: Examples of systems and methods for monitoring and optimizing battery performance for a site are disclosed. In some embodiments, sensor data pertaining to the site may be obtained. Based on the sensor data and historical data of the site, one or more anomaly events is predicted by a first machine learning model. The one or more anomaly events may further be classified into critical event and non-critical event. In case of the critical events, one or more commands may be sent to an edge device installed at the site to perform corrective actions.
    Type: Application
    Filed: January 3, 2024
    Publication date: June 27, 2024
    Inventors: Ashok Juneja, Shweta Singh
  • Patent number: 11992528
    Abstract: The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: May 28, 2024
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Tony W. Liang, Andrei William Konradi, Shweta Singh
  • Publication number: 20240115724
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 19, 2023
    Publication date: April 11, 2024
    Inventors: Shweta SINGH, Jennifer Hope RICHARDSON, Laura Patterson SERWER, Jonathan Alexander TERRETT, Susan E. MORGAN-LAPPE, Tracy HENRIQUES, Sherry L. RALSTON, Marvin Robert LEANNA, Ilaria BADAGNANI
  • Publication number: 20240079895
    Abstract: Examples of systems and methods for monitoring and optimizing battery performance for a site are disclosed. In an example, sensor data pertaining to the site may be obtained. Based on the sensor data and historical data of the site, one or more anomaly events is predicted by a first machine learning model (126). The one or more anomaly events may further be classified into critical event and non-critical event. In case of the critical events, one or more commands may be sent to an edge device (102) installed at the site to perform corrective actions.
    Type: Application
    Filed: October 18, 2022
    Publication date: March 7, 2024
    Inventors: Ashok Juneja, Shweta Singh
  • Publication number: 20240076374
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 18, 2023
    Publication date: March 7, 2024
    Inventors: James William WEST, Jason Gary SAGERT, Jonathan Alexander TERRETT, Annie Yang WEAVER, Luc Roland DESNOYERS, Shweta SINGH
  • Publication number: 20240002348
    Abstract: The present invention relates to quinolones of formula (I) and process for its preparation by amine insertion into aryl-ynones thereof. [Formula I] The invention further relates to the process to obtain the natural products such as: graveoline, graveolinine, pseudane IV, pseudane VII, pseudane VIII and pseudane XII. The invention also describes the process for the total synthesis of waltherione F in concise approach from the quinolone synthesized.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 4, 2024
    Inventors: Srihari PABBARAJA, Goverdhan MEHTA, Shweta SINGH
  • Publication number: 20230331841
    Abstract: A population of genetically engineered T cells, comprising a nucleic acid encoding an anti-CD83 CAR, a disrupted Reg1 gene, and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD83 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-?, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Application
    Filed: March 22, 2023
    Publication date: October 19, 2023
    Inventors: Daniel Robert HOSTETTER, Shweta SINGH, Jonathan TERRETT
  • Patent number: 11753466
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 12, 2023
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Publication number: 20230252372
    Abstract: System and methods for material dataflow extraction and simulation for bottom-up physical input-output table (PIOT) generation is provided. The system may receive an engineering model and an industry classification. The system may determine the type of engineering model. The system may execute the engineering model to generate the flow data. The system may build an physical supply use table (PSUT) for the region by determining, based on a flow type of data generated by the engineering model and the industry classification, a cell location in the PSUT. The system may store the data in the cell location of the PSUT. The system may generate a physical input output table (PIOT) based on PSUTs generated based for a plurality of industries.
    Type: Application
    Filed: July 6, 2021
    Publication date: August 10, 2023
    Applicant: Purdue Research Foundation
    Inventors: Shweta Singh, Carol X. Song, Venkata Sai Gargeya Vunnava
  • Publication number: 20230203186
    Abstract: Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.
    Type: Application
    Filed: July 1, 2022
    Publication date: June 29, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Vinay Bhaskar, Erin Willert
  • Publication number: 20230037373
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: August 31, 2022
    Publication date: February 9, 2023
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Publication number: 20220306759
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: February 8, 2022
    Publication date: September 29, 2022
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • Patent number: 11434304
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: September 6, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 11414496
    Abstract: Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: August 16, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Vinay Bhaskar, Erin Willert
  • Publication number: 20220169609
    Abstract: The present invention relates to carbazoles of general formula (I), and process for the preparation thereof: wherein ‘R1’ is H, C1-C6 alkyl, benzyl, or allyl; R2 is H, C1-C6 alkyl, cyclopropyl, phenyl, aryl, heteroaryl, or NO2; R3 is H, C1-C6 alkyl, cyclopropyl, phenyl aryl, heteroaryl, 4-methoxy phenyl, 4-ethyl phenyl, 2-methyl phenyl, or 2-Fluoro phenyl; R4 is H, benzoyl, —CO2Et, —CHO, Br, or —OMe; R5 is OH, OMOM, OMe, CN, or OTf; R6 is H, or O-alkyl; and R3-R4 is —CHNCH2CH2-. This invention also relates to the process for the preparation of carbazomycin A of Formula (1), calothrixin B of Formula (2) and staurosporinone of Formula (3) involving carbazoles of general formula (I) as an intermediate.
    Type: Application
    Filed: March 24, 2020
    Publication date: June 2, 2022
    Inventors: Srihari PABBARAJA, Goverdhan MEHTA, Ramesh SAMINENI, Shweta SINGH
  • Publication number: 20220088192
    Abstract: The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.
    Type: Application
    Filed: April 9, 2021
    Publication date: March 24, 2022
    Inventors: Henry Bernard LOWMAN, Luc Roland DESNOYERS, Tony W. LIANG, Andrei William KONRADI, Shweta SINGH
  • Patent number: 11267896
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: March 8, 2022
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • Patent number: 11240255
    Abstract: A method involves: receiving a request to access a first online financial application from a client device, where the first online financial application is one of a many online financial applications made available by an online financial service, and where the many online applications includes a second online application; attempting to generate a browser fingerprint for a browser application on the client device by applying a fingerprinting algorithm to one or more items of browser metadata; associating the browser fingerprint, if generated, with external user data obtained from a web analytics tool and internal user data obtained from the online financial service; receiving login credentials for the first online financial application from a user of the client device; retrieving, using the login credentials, additional internal user data maintained by the online financial service; personalizing, upon detecting the browser fingerprint and using the external user data, the internal user data, and the additional
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 1, 2022
    Assignee: Intuit Inc.
    Inventors: Ali Amin, Lewis Dawson, Shweta Singh, Tim Spaulding, Josh Rab, Giovanna Diaz, Tera Thomas, Gonzalo Galicia
  • Publication number: 20210145978
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 20, 2021
    Inventors: Shweta Singh, Jennifer Hope Richardson, Laura Patterson Serwer, Jonathan Alexander Terret, Susan E. Morgan-Lappe, Tracy Henriques, Sherry L. Ralston, Marvin Robert Leanna, Ilari Badagnani, Sahana Bose